Medications for the treatment of narcolepsy

Expert Opinion on Emerging Drugs

Volumn 6, Issue 2, 2001, Pages 239-247

  Black, Jed ^a   Guilleminault, Christian ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Anticataplectics; Cataplexy; Narcolepsy; Sleepiness; Stimulants; Wake promoting therapeutics

Indexed keywords

4 HYDROXYBUTYRIC ACID; AMPHETAMINE; ATTENADE; CENTRAL STIMULANT AGENT; CLOMIPRAMINE; DESIPRAMINE; DEXAMPHETAMINE; DOPAMINE UPTAKE INHIBITOR; FLUOXETINE; IMIPRAMINE; MAZINDOL; METADATE MR; METHAMPHETAMINE; METHYLIN ER; METHYLPHENIDATE; MODAFINIL; OREXIN; OROS; OXYBATE SODIUM; PEMOLINE; PEMOLINE MAGNESIUM; PERCEPTIN; PROTRIPTYLINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ANOREXIA; BRAIN ATROPHY; CATAPLEXY; CONSTIPATION; FATIGUE; GENE LOCUS; GENE MUTATION; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; IRRITABILITY; LIVER TOXICITY; NARCOLEPSY; NERVOUSNESS; PREVALENCE; REM SLEEP; REVIEW; SIDE EFFECT; SOMNOLENCE; TACHYPHYLAXIS; TREMOR; URINE RETENTION; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0035493676     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.6.2.239     Document Type: Review

References (34)

1. Sleep paralysis
2. Evaluation of short-term and long term treatment of the narcolepsy syndrome with clomipramine hydrochloride
3. Pharmacological aspects of human and canine narcolepsy
4. Clinical and polygraphic development of narcolepsy
5. Twenty-four-hour recording in REM-narcoleptics with special reference to nocturnal sleep disruption
6. Clinical features of narcolepsy: Japanese experience in HLA in narcolepsy
7. Stability of cataplexy over several months-information for the design of therapeutic trial
8. Narcolepsy
9. The prevalence of narcolepsy
10. The prevalence of narcolepsy: An epidemiological study of the Finnish twin cohort
11. Genetic and familial aspects of narcolepsy
12. Narcolepsy in Negroes
13. Hypnagogic and hypnopompic hallucinations: Pathological phenomena?
14. Psychosocial aspects of narcolepsy
15. Comparison of the psychosocial effects of epilepsy and narcolepsy/cataplexy: A controlled study
16. Treatment of narcolepsy: Objective studies on methylphenidate, pemoline, and protriptyline
17. Relative efficacy of drugs for the treatment of sleepiness in narcolepsy
18. Patterns of sleep and wakefulness in treated narcoleptic subjects
19. Compliance with stimulant medications in patients with narcolepsy
20. Treatment of narcolepsy with Ritalin
21. Natural history, symptoms and treatment of the narcoleptic syndrome
22. Dopaminergic role in stimulant-induced wakefulness
23. Canine cataplexy is preferentially controlled by adrenergic mechanisms: Evidence using monoamine selective uptake inhibitors and release enhancers
24. Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds
25. Pharmacological aspects of human and canine narcolepsy
26. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants
27. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene
28. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation
29. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains
30. Narcolepsy: Although people with the disorder do not fall face-first into their soup as in the movies, narcolepsy is still a mysterious disease. But science has new leads
31. Hypocretin (orexin) deficiency in human narcolepsy
32. On the treatment of REM narcolepsy